Report cover image

Global Cancer Biomarkers Market Size study, by Technology, Application, End Use, Product Type, and Regional Forecasts 2022-2032

Publisher Bizwit Research & Consulting
Published May 10, 2025
Length 285 Pages
SKU # BIZW20037540

Description

Global Cancer Biomarkers Market is valued approximately at USD 4.96 billion in 2023 and is anticipated to grow with a steady CAGR of more than 6.19% over the forecast period 2024–2032. Cancer biomarkers—biological molecules that indicate the presence or progression of malignancy—have fundamentally reshaped the way clinicians detect, diagnose, and treat cancer. Their application spans from early screening and diagnostic testing to predicting disease recurrence and evaluating therapeutic response. As precision medicine continues to steer the future of oncology, cancer biomarkers have evolved from supportive tools to central components of decision-making frameworks. The growing emphasis on individualized treatment, supported by biomarker-driven drug development, is fostering the widespread adoption of cancer biomarker testing across both developed and emerging healthcare systems.

The rapid advancement in analytical technologies such as mass spectrometry, flow cytometry, and high-throughput sequencing has drastically enhanced the sensitivity, specificity, and utility of biomarker assays. With pharmaceutical companies prioritizing biomarker validation in clinical trials and regulatory bodies encouraging biomarker-based companion diagnostics, demand for robust platforms capable of real-time detection has escalated. Nonetheless, challenges such as biomarker heterogeneity, high development costs, and complex regulatory pathways hinder seamless commercialization. In parallel, the lack of standardized validation protocols for novel biomarkers has raised concerns regarding reproducibility and diagnostic accuracy.

Biomarker testing is increasingly integrated across diverse oncology applications, ranging from breast and colorectal cancers to more complex immuno-oncology landscapes. Software-driven platforms offering AI-powered insights, predictive modeling, and digital pathology are amplifying the role of biomarkers in clinical and research settings. Hardware and analytical tools embedded within hospital labs and CROs are enabling real-time quantification of biomarker expression, pushing the frontiers of therapeutic personalization. Simultaneously, service-based offerings, including biomarker discovery and validation services, are gaining traction among biotech firms and academic institutions seeking scalable solutions without infrastructure investments.

From quality control in production labs to research-intensive drug discovery units, the cancer biomarker ecosystem is diversifying rapidly. Real-time monitoring of biomarker levels to guide therapeutic dosing, track resistance mechanisms, and monitor relapse probabilities is becoming integral to treatment pathways. Moreover, applications extend into biotechnology, food safety, and chemical process monitoring, where biomarkers help ensure biological stability or detect unintended contamination. As healthcare transitions into an outcomes-based reimbursement model, the importance of actionable biomarkers for early intervention is surging.

Regionally, North America dominates the cancer biomarkers market, owing to its established genomics infrastructure, early adoption of personalized medicine, and high volume of oncology research. The United States leads globally in biomarker innovation, supported by funding from both public health bodies and biopharmaceutical giants. Europe follows, especially in countries like Germany, France, and the UK, where strong academic-industry collaborations fuel research. Meanwhile, the Asia Pacific region is expected to grow at the fastest pace, driven by increasing cancer prevalence, expansion of healthcare coverage, and strategic investments in biomarker research across India, China, and Japan. Latin America and the Middle East & Africa are also registering growing awareness and integration of biomarker-led diagnostics in oncology care.

Major market player included in this report are:
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Abbott Laboratories
• Roche Diagnostics
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Merck KGaA
• Becton, Dickinson and Company
• Danaher Corporation
• Genomic Health, Inc.
• Myriad Genetics, Inc.
• Bio-Techne Corporation

The detailed segments and sub-segment of the market are explained below:

By Technology
• Spectroscopy
• Chromatography
• Mass Spectrometry
• Flow Cytometry

By Application
• Pharmaceuticals
• Biotechnology
• Food and Beverage
• Chemical Processing

By End Use
• Quality Control
• Research and Development
• Production Monitoring

By Product Type
• Software
• Hardware
• Services

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Cancer Biomarkers Market Executive Summary
1.1. Global Cancer Biomarkers Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Technology
1.3.2. By Application
1.3.3. By End Use
1.3.4. By Product Type
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cancer Biomarkers Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Cancer Biomarkers Market Dynamics
3.1. Market Drivers
3.1.1. Rising Cancer Incidence and National Screening Initiatives
3.1.2. Advances in High-Sensitivity Analytical Technologies
3.1.3. Shift toward Precision Oncology and Companion Diagnostics
3.2. Market Challenges
3.2.1. Biomarker Heterogeneity and Validation Complexity
3.2.2. High Development Costs and Regulatory Hurdles
3.3. Market Opportunities
3.3.1. Integration of AI-Powered Data Analytics
3.3.2. Expansion into Emerging Healthcare Markets
3.3.3. Growth of Multiplex and Point-of-Care Testing Platforms
Chapter 4. Global Cancer Biomarkers Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Cancer Biomarkers Market Size & Forecasts by Technology 2022–2032
5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Spectroscopy
5.2.2. Chromatography
5.2.3. Mass Spectrometry
5.2.4. Flow Cytometry
Chapter 6. Global Cancer Biomarkers Market Size & Forecasts by Application 2022–2032
6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Pharmaceuticals
6.2.2. Biotechnology
6.2.3. Food and Beverage
6.2.4. Chemical Processing
Chapter 7. Global Cancer Biomarkers Market Size & Forecasts by End Use 2022–2032
7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Quality Control
7.2.2. Research and Development
7.2.3. Production Monitoring
Chapter 8. Global Cancer Biomarkers Market Size & Forecasts by Product Type 2022–2032
8.1. Segment Dashboard
8.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
8.2.1. Software
8.2.2. Hardware
8.2.3. Services
Chapter 9. Global Cancer Biomarkers Market Size & Forecasts by Region 2022–2032
9.1. North America Market
9.1.1. U.S. Market
9.1.1.1. Technology breakdown, 2022–2032
9.1.1.2. Application breakdown, 2022–2032
9.1.2. Canada Market
9.2. Europe Market
9.2.1. UK Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific Market
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of Asia Pacific Market
9.4. Latin America Market
9.4.1. Brazil Market
9.4.2. Mexico Market
9.4.3. Rest of Latin America Market
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of Middle East & Africa Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Thermo Fisher Scientific Inc.
10.1.2. Siemens Healthineers
10.1.3. Abbott Laboratories
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Thermo Fisher Scientific Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Siemens Healthineers
10.3.3. Abbott Laboratories
10.3.4. Roche Diagnostics
10.3.5. Agilent Technologies, Inc.
10.3.6. PerkinElmer, Inc.
10.3.7. Bio-Rad Laboratories, Inc.
10.3.8. QIAGEN N.V.
10.3.9. Illumina, Inc.
10.3.10. Merck KGaA
10.3.11. Becton, Dickinson and Company
10.3.12. Danaher Corporation
10.3.13. Genomic Health, Inc.
10.3.14. Myriad Genetics, Inc.
10.3.15. Bio-Techne Corporation
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
List of Tables
TABLE 1. Global Cancer Biomarkers Market, report scope
TABLE 2. Market estimates & forecasts by Region 2022–2032 (USD Million)
TABLE 3. Market estimates & forecasts by Technology 2022–2032 (USD Million)
TABLE 4. Market estimates & forecasts by Application 2022–2032 (USD Million)
TABLE 5. Market estimates & forecasts by End Use 2022–2032 (USD Million)
TABLE 6. Market estimates & forecasts by Product Type 2022–2032 (USD Million)
TABLE 7. North America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 8. U.S. market estimates & forecasts by segment, 2022–2032 (USD Million)
TABLE 9. Canada market estimates & forecasts by segment, 2022–2032 (USD Million)
TABLE 10. Europe market estimates & forecasts, 2022–2032 (USD Million)
TABLE 11. Asia Pacific market estimates & forecasts, 2022–2032 (USD Million)
TABLE 12. Latin America market estimates & forecasts, 2022–2032 (USD Million)
TABLE 13. Middle East & Africa market estimates & forecasts, 2022–2032 (USD Million)
TABLE 14. Company market share analysis (2023)
TABLE 15. Forecasting methodology overview
TABLE 16. Supply-side assessment
TABLE 17. Demand-side assessment
TABLE 18. PESTEL summary
TABLE 19. Porter’s Five Forces summary
TABLE 20. Key investment opportunities
List of Figures
FIGURE 1. Global market research methodology
FIGURE 2. Global market estimation techniques
FIGURE 3. Global market size estimates & forecast methods
FIGURE 4. Global key trends 2023
FIGURE 5. Global growth prospects 2022–2032
FIGURE 6. Global Porter’s Five Forces model
FIGURE 7. Global PESTEL analysis
FIGURE 8. Global value chain analysis
FIGURE 9. By Technology, 2022 & 2032 (USD Million)
FIGURE 10. By Application, 2022 & 2032 (USD Million)
FIGURE 11. By End Use, 2022 & 2032 (USD Million)
FIGURE 12. By Product Type, 2022 & 2032 (USD Million)
FIGURE 13. Regional snapshot 2022 & 2032
FIGURE 14. North America, 2022 & 2032 (USD Million)
FIGURE 15. Europe, 2022 & 2032 (USD Million)
FIGURE 16. Asia Pacific, 2022 & 2032 (USD Million)
FIGURE 17. Latin America, 2022 & 2032 (USD Million)
FIGURE 18. Middle East & Africa, 2022 & 2032 (USD Million)
FIGURE 19. Competitive landscape heat map (2023)
FIGURE 20. Forecast sensitivity analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us